Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia-Reference-Cited by-同舟云学术

Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia

Published:2021-05-22 Issue:8 Volume:96 Page:945-953
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Abeykoon Jithma P.¹^ORCID,Zanwar Saurabh¹^ORCID,Ansell Stephen M.¹^ORCID,Muchtar Eli¹^ORCID,He Rong²^ORCID,Greipp Patricia T.³^ORCID,King Rebecca L.²,Ailawadhi Sikander⁴^ORCID,Paludo Jonas¹^ORCID,Larsen Jeremy T.⁵,Habermann Thomas M.¹,Inwards David¹^ORCID,Go Ronald S.¹,Thanarajasingam Gita¹,Buadi Francis¹,Dispenzieri Angela¹^ORCID,Thompson Carrie A.¹,Witzig Thomas E.¹^ORCID,Lacy Martha¹,Gonsalves Wilson¹^ORCID,Nowakowski Grzegorz S.¹,Dingli David¹,Rajkumar Sundararajan Vincent¹^ORCID,Kyle Robert A.¹,Sher Taimur⁴,Roy Vivek⁴,Rosenthal Allison⁵^ORCID,Chanan‐Khan Asher A.⁴,Reeder Craig⁵,Gertz Morie A.¹^ORCID,Kumar Shaji¹^ORCID,Kapoor Prashant¹^ORCID

Affiliation:

1. Division of Hematology Mayo Clinic Rochester Minnesota USA

2. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA

3. Division of Laboratory Genetics and Genomics Mayo Clinic Rochester Minnesota USA

4. Division of Hematology and Oncology Mayo Clinic Jacksonville Florida USA

5. Division of Hematology Mayo Clinic Phoenix Arizona USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26210

Reference37 articles.

1. Diagnosis and Management of Waldenström Macroglobulinemia

2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

3. Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

4. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review

5. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy;Journal of Zhejiang University-SCIENCE B;2024-08

2. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis;Leukemia & Lymphoma;2023-12-29

3. Advances in Treatment of Waldenström Macroglobulinemia;Current Oncology Reports;2023-10-19

4. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenström's Macroglobulinemia?;Journal of Clinical Oncology;2023-08-20

5. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy;Hematology/Oncology Clinics of North America;2023-08